Dazoxiben

Dazoxiben is a thromboxane antagonist. It was developed by Eisai Co. and has been used in clinical trials for the treatment of asthma.

History

Dazoxiben was developed by the Japanese pharmaceutical company Eisai Co. It was primarily researched as a potential treatment for asthma, due to its ability to inhibit the action of thromboxane.

Mechanism of Action

Dazoxiben works by antagonizing the action of thromboxane A2, a compound that promotes platelet aggregation and vasoconstriction. By inhibiting the action of thromboxane A2, Dazoxiben can potentially reduce the symptoms of asthma.

Clinical Trials

Dazoxiben has been tested in clinical trials for its potential use in treating asthma. However, the results of these trials have not been conclusive, and the drug is not currently approved for use in any country.

See Also

• Thromboxane A2
• Eisai Co.
• Asthma

References

Dazoxiben Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski